Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hypertension
Interventions
Nebivolol, Valsartan and Hydrochlorothiazide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
135
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more
Conditions
Hypertension
Interventions
nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
75
States / cities
Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more
Conditions
Preeclampsia, Pregnancy
Interventions
Mitoquinol Mesylate, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Inflammation, Cancer, Pain, Hypertension
Interventions
Sulindac
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
Up to 75 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Tucson, Arizona • Stony Brook, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
iRF System Hepatic Denervation
Device
Lead sponsor
Metavention
Industry
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more
Conditions
Adrenocortical Carcinoma
Interventions
Relacorilant, Pembrolizumab
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Stanford, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Conditions
Hypertension
Interventions
Home BP;secure messaging;pharmaceutical care;
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
25 Years to 75 Years
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Results available

Postpartum Weight Loss for Women at Elevated Cardiovascular Risk

NCT04914819
Conditions
Weight Loss, Postpartum Weight Retention, Hypertension in Pregnancy, Diabetes Mellitus in Pregnancy, Preeclampsia, Recruitment
Interventions
Online Behavioral Weight Loss Program, Virtual weigh-in
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Uncontrolled Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more
Completed No phase listed Observational Results available

Measuring Intraabdominal Pressure, Lactic Acid, and Urine Output

NCT05070572
Conditions
Intra-Abdominal Hypertension, Inguinal Hernia
Interventions
Accuryn Monitoring System
Device
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions
inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 1 Week
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Glaucoma
Interventions
Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Hypertension
Interventions
ramipril, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 16 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
39
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 33 more
Completed Not applicable Interventional Results available

Piloting Healthcare Coordination in Hypertension

NCT02988193
Conditions
Hypertension
Interventions
optima4BP Medication Management
Device
Lead sponsor
Optima Integrated Health
Industry
Eligibility
21 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Carlos, California
Completed Phase 1Phase 2 Interventional Results available

Health Evaluation in African Americans Using RAS Therapy

NCT02471833
Conditions
Alzheimer's Disease
Interventions
Telmisartan 20mg, Telmisartan 40mg, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Conditions
Screening
Interventions
$5 gift card, $100 monthly drawing
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Conditions
Chronic Hypertension in Pregnancy
Interventions
Remote Patient Monitoring
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Completed Phase 1 Interventional Results available

Olmesartan Pediatric Pharmacokinetic (PK) Study

NCT00151814
Conditions
Hypertension
Interventions
Olmesartan medoxomil
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
12 Months to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Little Rock, Arkansas • La Jolla, California • Louisville, Kentucky + 2 more
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetes, Hypercholesterolaemia, Hypertension, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Heart Failure, CAD - Coronary Artery Disease, Stroke Risk, Cardiac Arrythmias, Genetics Hypertension, Genetics, Pharmacogenomics, Pharmacogenomic Testing for Medication Management, Cancer Genetics
Interventions
Color Genomics Genetic Testing Panels
Genetic
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Conditions
Hypertension
Interventions
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Foley, Alabama • Carmichael, California • Los Angeles, California + 33 more